• Molecular NameGriseofulvin
  • SynonymGriseofulvina [INN-Spanish]; Griseofulvine [INN-French]; Griseofulvinum [INN-Latin]
  • Weight352.77
  • Drugbank_IDDB00400
  • ACS_NO126-07-8
  • Show 2D model
  • LogP (experiment)2.15
  • LogP (predicted, AB/LogP v2.0)2.51
  • pkaN/A
  • LogD (pH=7, predicted)2.51
  • Solubility (experiment)0.00864 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-4.29
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors0
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds3
  • TPSA71.06
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antifungal drug. It is used both in animals and in humans, to treat fungal infections of the skin (commonly known as ringworm) and nails.
  • Absorption_valueN/A
  • Absorption (description)Poorly absorbed from GI ranging from 25 to 70% of an oral dose. Absorption is significantly enhanced by administration with or after a fatty meal.
  • Caco_2N/A
  • Bioavailability27.0
  • Protein binding84.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic demethylation and glucuronidation
  • Half life9~21 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySide effects are minor: headaches, gastrointestinal reactions and cutaneous eruptions
  • LD50 (rat)N/A
  • LD50 (mouse)N/A